IVEN THE SIMILARITIES between alendronate (Fosamax) and risedronate (Actonel), the only two bisphosphonates approved for treating and preventing osteoporosis in the United States, how should clinicians decide which to use in a given patient?
Alendronate and risedronate have similar mechanisms of action, pharmacokinetics, drug interaction profiles, and administration guidelines. Additionally, evaluation of individual drug studies indicates comparable efficacy between the two agents.
The decision as to which bisphosphonate to prescribe for osteoporosis will be influenced by differences in their adverse event profiles (which are being assessed in ongoing trials) and dosing regimens (once a week vs once a day).
s RANGE OF TREATMENTS
A variety of nonpharmacologic and pharmacologic interventions are available for preventing and treating osteoporosis. Adequate intake of calcium and vitamin D, regular exercise, smoking cessation, and limiting alcohol intake are recommended initially. Drug treatment options include estrogen replacement, raloxifene, calcitonin, calcitriol, and bisphosphonates (currently only alendronate and risedronate).
s INDICATIONS FOR BISPHOSPHONATES
Risedronate is approved by the US Food and Drug Administration (FDA) for preventing and treating postmenopausal osteoporosis and glucocorticoid-induced osteoporosis and for treating Paget disease of the bone.
Alendronate is also FDA-approved for treating Paget disease, for preventing and s KEY POINTS Both alendronate and risedronate have been found effective in placebo-controlled trials in preventing and treating osteoporosis.
Alendronate and risedronate are generally well tolerated as long as they are taken appropriately to avoid upper gastrointestinal adverse effects.
Alendronate is slightly more expensive than risedronate; however, the once-weekly form of alendronate may enhance patient compliance and tolerability enough to offset the higher cost.
treating postmenopausal osteoporosis, and for treating glucocorticoid-induced osteoporosis-but not for preventing glucocorticoidinduced osteoporosis.
s MECHANISM OF ACTION
The mechanism of action of bisphosphonates is not fully understood. Experimental and clinical studies show that at the tissue level they inhibit bone resorption and bone turnover without directly suppressing bone formation, resulting in increased bone mass and mineralization.
Some experts suggest that bisphosphonates work by inhibiting osteoclast formation, recruitment, and activity, or by reducing the life span of osteoclasts by inducing apoptosis.
Bisphosphonates may also act intracellular- Patients: 224 men and women ages 18 to 65 who had begun long-term prednisone therapy (7.5 mg or more per day) within the past 3 months and had not used estrogen within the past year Treatments: Risedronate 2.5 mg or 5.0 mg once daily or placebo for 1 year Results: Significant change in bone mineral density of the lumbar spine in both risedronate groups vs baseline (P not recorded); increased bone mineral density in the lumbar spine, femoral neck, and trochanter with risedronate 5 mg/day vs placebo (P < .001) Adverse effects: Similar incidence in all three groups
Investigators: Reid et al 9
Patients: 290 men and women who had been on long-term prednisone therapy (7.5 mg or more per day) or equivalent for more than 6 months and had not used oral estrogen in the past 6 months Treatments: Risedronate 2.5 mg or 5.0 mg once daily or placebo for 1 year Results: Increased bone mineral density in the lumbar spine, femoral neck, and trochanter with risedronate 5 mg/day vs baseline (P < .001) and vs placebo (P < .05); incidence of vertebral fractures 5% with risedronate 5 mg/day vs 15% with placebo (P = .042) Adverse effects: Similar incidence of upper GI events in the risedronate 5 mg/day and placebo groups
Study with alendronate

Investigators: Saag et al 10
Patients: 477 men and women who had been taking prednisone (7.5 mg/day or more) or an equivalent for at least 4 months and could have used estrogen Treatments: Alendronate 5 mg once daily or 10 mg once daily or placebo for 12 months Results: Increased bone mineral density in the lumbar spine, femoral neck, trochanter, and total body with alendronate 10 mg/day vs baseline (P < .01) and vs placebo (P < .01) Adverse effects: No difference in serious adverse events among the three groups; a small increase in nonserious upper GI effects occurred with alendronate 10 mg/day
T A B L E 3
Avoid using these drugs in pregnant and nursing women ed upper GI adverse effects as did patients receiving active drug.
Miller et al 11 addressed this issue in a placebo-controlled trial of alendronate rechallenge in 172 postmenopausal women with osteoporosis, all of whom had stopped taking alendronate because of adverse upper GI events that occurred while taking the drug. After 8 weeks of rechallenge therapy, 14.5% of patients receiving alendronate and 17.3% of patients receiving placebo had stopped treatment because of upper GI complaints, including abdominal pain (29.6%), acid regurgitation (25.9%), nausea (18.5%), and gastroesophageal reflux (11.1%). The investigators suggested that upper GI complaints reported during alendronate therapy reflected a high background incidence of upper GI complaints rather than an adverse effect of alendronate. 11 In another study, conducted by Adachi et al, 12 66 postmenopausal women who had previously stopped taking alendronate because of upper GI adverse effects received either risedronate 5 mg daily or placebo. After 3 months, 16.1% of patients had stopped taking placebo, compared with 11.4% of patients receiving risedronate. The investigators concluded that risedronate is as well tolerated as placebo in patients who cannot tolerate alendronate.
Are there any differences in GI adverse effects? Lanza et al 13 assessed the effects of alendronate and risedronate on the incidence of gastric ulcers and on the esophageal and gastroduodenal mucosa in 515 postmenopausal women age 40 and older. Patients received either risedronate 5 mg/day or alendronate 10 mg/day for 14 days, while abstaining from alcohol, smoking, and nonsteroidal antiinflammatory drugs.
Gastric ulcer, defined as a break of at least 3 mm in the gastroduodenal mucosa extending through the muscularis mucosa, was observed endoscopically in 4.1% of the risedronate group vs 13.2% of the alendronate group (P < .001). The investigators concluded that at doses used for osteoporosis treatment, risedronate was associated with a significantly lower incidence of gastric ulcers than alendronate.
However, this study had several drawbacks: it was a short-term study in healthy postmenopausal women and did not include a placebo group to determine the expected risks of gastric ulceration without intervention. The clinical relevance of the small asymptomatic ulceration observed remains unclear. 14 Higher doses tested. Lanza et al 15 also assessed the potential of alendronate and risedronate to cause endoscopically observed upper GI mucosal irritation, using the highest approved doses (ie, those used in the treatment of Paget disease) and a scale for scoring mucosal erosions.
After a 28-day trial of alendronate 40 mg a day, risedronate 30 mg a day, placebo, or placebo with aspirin 650 mg four times a day for the last 7 days, patients taking risedronate and alendronate had comparable gastric and duodenal erosion scores, and these scores were significantly lower than those in patients taking aspirin. 15 Esophageal erosion scores were comparable in all groups.
However, gastric ulcers (defined as larger, deeper endoscopic erosions) occurred in 3% of patients taking risedronate or alendronate, in 60% of patients taking aspirin, and in none of the patients in the placebo group. Adverse GI effects were reported by 12% in the alendronate group, 15% in the risedronate group, 35% in the aspirin group, and 22% in the placebo group.
The investigators concluded that alendronate and risedronate are generally well tolerated and that they pose a very low risk for clinically important gastric irritation, even at the highest dosages used.
s MINIMAL DRUG INTERACTIONS
Neither risedronate nor alendronate induces or inhibits the cytochrome P450 enzyme system, so interaction with other drugs is minimal. However, clinicians should note the following:
• Co-administration of calcium supplements, antacids, or oral medications with divalent cations interfere with absorption of risedronate and alendronate • The concomitant use of aspirin and highdose alendronate should be avoided because of an increased incidence of upper GI adverse events in clinical trials.
Upper GI adverse effects were similar to those of placebo s DOSAGE 
Once-weekly dosing
Of note, Merck, Inc. recently received FDA approval to market two new dosage strengths of alendronate for once-weekly dosing: a 35-mg tablet for the prevention of postmenopausal osteoporosis and a 70-mg tablet for the treatment of osteoporosis. This modified dosing schedule for treatment is based on a recent study by Schnitzer et al 16 comparing the efficacy and safety of oral doses of alendronate 70 mg once a week (n = 519), 35 mg twice a week (n = 369), and 10 mg once every day (n = 370). In a 1-year, doubleblind, multicenter study of postmenopausal women with osteoporosis, all three regimens produced similar increases in bone mineral density at the lumbar spine, total hip, femoral neck, trochanter, and total body. All three regimens were well tolerated with no statistically significant differences in the most commonly reported upper GI events, including abdominal pain, nausea, dyspepsia, and acid regurgitation. Also, a trend towards a lower incidence of esophageal, gastric, or duodenal adverse effects was observed with once-a-week and twice-aweek dosing vs daily dosing. The authors concluded that alendronate 70 mg once a week is a more convenient alternative to daily dosing and may enhance compliance.
Given the apparent advantages of onceweekly alendronate dosing, Woodson et al 17 reported a trial of risedronate 30 mg once a week for 12 months in 13 postmenopausal women with osteoporosis who did not tolerate FDA-approved therapies. Increases in bone mineral density from baseline were seen in the lumbar spine, femoral neck, and total hip, and the treatment was well tolerated. Statistical analysis was not available. 
T A B L E 5
Avoid giving high-dose alendronate with aspirin s COST 
